<DOC>
	<DOC>NCT02417870</DOC>
	<brief_summary>To investigate the safety and tolerability of treatment with low dose rIL-2 in renal transplant recipients. To assess the immunologic impact of low dose rIL-2 in renal transplant recipients. To assess the efficacy of low dose rIL-2 in renal transplant recipients.</brief_summary>
	<brief_title>Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Kidney transplant recipients &gt;18 years and &lt;75 years of age &gt;6 months post Tx on stable dose of immunosuppression Transplant biopsy showing interstitial fibrosis and tubular atrophy of grade II or greater, with some evidence of lymphocytic infiltration (biopsy is NOT a study procedure, it would be performed as part of the patient's SOC) Ability to give informed consent Biopsy proven acute cellular rejection; greater than grade 1A Baseline creatinine &gt;3.5mg/dL Patients with active infection, including Hepatitis B and C, HIV Current or prior invasive malignancy Patients who are pregnant or breastfeeding Patients who are unable to give consent Prior intolerance of/allergy to IL2 Inability to comply with treatment History of thrombotic angiopathy including hemolytic uremic syndrome and thrombotic thrombocytopenic purpura Symptomatic congestive cardiac failure or uncontrolled cardiac angina Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug. WOCBP and male subjects with reproductive potential must agree to use a highly effective method of birth control [defined in protocol &amp; ICF] during study treatment, and for 6 months after completion of treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
</DOC>